The price of Lyra Therapeutics Inc (NASDAQ:LYRA) shares last traded on Wall Street fell -4.73% to $0.33.
LYRA stock price is now -92.17% away from the 50-day moving average and -92.15% away from the 200-day moving average. The market capitalization of the company currently stands at $19.88M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $10 to $0.50, Jefferies Downgraded its rating from Buy to Hold for Lyra Therapeutics Inc (NASDAQ: LYRA). On May 07, 2024, H.C. Wainwright Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $12 to quote $2, while ‘BofA Securities’ rates the stock as ‘Underperform’
In other news, Waksal Harlan, Executive Chair bought 25,000 shares of the company’s stock on Nov 10 ’23. The stock was bought for $74,095 at an average price of $2.96. Upon completion of the transaction, the Executive Chair now directly owns 261,966 shares in the company, valued at $86448.78. An SEC document containing details of the transaction can be found on the SEC’s website. On May 31 ’23, Director PERCEPTIVE ADVISORS LLC bought 3,610,832 shares of the business’s stock. A total of $8,999,999 was incurred on buying the stock at an average price of $2.49. This leaves the insider owning 11,469,117 shares of the company worth $3.78 million. A total of 20.58% of the company’s stock is owned by insiders.
During the past 12 months, Lyra Therapeutics Inc has had a low of $0.34 and a high of $6.79. As of last week, the company has a debt-to-equity ratio of 0.49, a current ratio of 4.78, and a quick ratio of 4.78. The fifty day moving average price for LYRA is $4.0429 and a two-hundred day moving average price translates $4.139275 for the stock.
The latest earnings results from Lyra Therapeutics Inc (NASDAQ: LYRA) was released for 2024-03-31. The net profit margin was -4099.82% and return on equity was -95.93% for LYRA. The company reported revenue of $0.53 million for the quarter, compared to $0.41 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 29.76 percent.
